Silencing of *Hint1*, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma

Yu-Jing Zhang^{a,*}, Haiyang Li^b, Hui-Chen Wu^a, Jing Shen^a, Lin Wang^b, Ming-Whei Yu^c, Po-Huang Lee^d, I. Bernard Weinstein^b, Regina M. Santella^a

^a Department of Environmental Health Sciences, Mailman School of Public Health of Columbia University, 630 W, 168th St., New York, NY 10032, USA

^b Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA

^c Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China

^d Department of Surgery, College of Medicine, National Taiwan University, Taipei, Taiwan, Republic of China

ARTICLE INFO

Article history:

Received 24 July 2008

Received in revised form 16 October 2008

Accepted 17 October 2008

Keywords:

Hint1

HCC

Epigenetic changes

Promoter hypermethylation

p16

Environmental carcinogens

ABSTRACT

The *Hint1* protein, a member of the histidine triad (HIT) family, is highly conserved in diverse species and ubiquitously expressed in mammalian tissues. Previous studies in mice provided evidence that *Hint1* may be haploinsufficient with respect to its function as a tumor suppressor. In the present study, we investigated the aberrant methylation of *Hint1* and explored possible relationships between aberrant methylation and clinicopathological features in hepatocellular carcinoma (HCC). Hypermethylation of *Hint1* was evaluated by the methylation specific PCR (MSP) method in 40 patients with HCC (tumor and paired adjacent non-tumor tissues) from Taiwan, 22 cases of normal liver tissue (14 from Taiwan and 8 from the US). *HINT1* expression in tissues was detected by immunohistochemistry. The frequencies of hypermethylation of *Hint1* in tumor, paired adjacent non-tumor and normal liver tissue were 55.0%, 37.5% and 9.1%, respectively. A statistically significant inverse association was found between *Hint1* methylation status and expression of the *HINT1* protein in tumor tissues ($p = 0.003$). The relationship between *Hint1* methylation status and clinical features and other, previously measured biomarkers was also analyzed. *p16* hypermethylation was statistically significantly associated with *Hint1* methylation status ($p = 0.035$). There were no correlations between *Hint1* methylation and hepatitis B (HBV) or hepatitis C (HCV) infection status or aflatoxin B₁ (AFB₁-) and polycyclic aromatic hydrocarbons (PAHs)-DNA adduct levels. These results suggest that promoter hypermethylation of *Hint1* may play a role in hepatocarcinogenesis.

© 2008 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world, and a leading cause of death in many countries. The epidemiology of HCC has marked demographic and geographic variations, occurring mainly in Africa and Asia. However, the incidence is also

increasing in the United States and Europe [1]. The major risks for the development of HCC have been identified as chronic hepatitis B virus (HBV) and hepatitis virus C (HCV) infections and several dietary or environmental factors, including aflatoxin B₁ (AFB₁) and polycyclic aromatic hydrocarbons (PAHs). HBV and HCV infections and AFB₁ exposure are responsible for approximately 80% of all HCCs [2,3]. As with other cancers, the development of HCC is a complex, multistep process [4]. The molecular pathogenesis of HCC appears to involve multiple genetic aberrations in the molecular control of hepatocyte proliferation, differentiation and death and the maintenance of genomic integrity. This process is influenced by the cumulative acti-

* Corresponding author. Tel.: +1 212 305 8158; fax: +1 212 305 5328.

E-mail address: yz6@columbia.edu (Y.-J. Zhang).

Abbreviations: *Hint1*, hit nucleotide binding protein-1; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; AFB₁, aflatoxin B₁; PAHs, polycyclic aromatic hydrocarbons.

vation and inactivation of oncogenes, tumor suppressor genes, cell cycle control genes and other genes.

The HINT protein, a member of the histidine triad (HIT) family, is highly conserved in diverse species and ubiquitously expressed in mammalian tissues. The HIT protein superfamily consists of at least three subfamilies: Hint, Fhit and Ga1T [5]. In previous studies, *Hint1* deleted mice had a marked increase in susceptibility to chemical carcinogen-induced gastric tumors [6], mammary tumors and ovarian tumors [7]. In addition, with aging, *Hint1* deleted mice displayed an increase in the occurrence of a variety of spontaneous tumors including HCC [7]. These studies in mice also provided evidence that *Hint1* may be haploinsufficient with respect to its function as a tumor suppressor gene. Mechanistic studies indicate that *Hint1* can play a role in apoptosis and *p53* expression [8] and that it can bind to and inhibit several transcription factors including MITF, USF2 and β -catenin and also inhibit AP-1 activity by binding to POSH [9]. It had been reported that *Hint1* is transcriptionally silenced in some human non-small cell lung cancer (NSCLC) cell lines and that increased expression of *Hint1* inhibits growth of the NSCLC cell lines H522 and H538 [10]. Similar effects have been seen in colon cancer cells [9].

During the past decade, extensive studies in the field of epigenetics have brought an awareness that not only genetic, but also epigenetic changes, play a very important role in carcinogenesis [11,12]. DNA methylation is one of the best understood epigenetic mechanisms; hypermethylation of normally unmethylated CpG islands, which are CpG dinucleotide-rich areas located mainly in the promoter regions of many genes, correlate with loss of transcription and loss of gene function [13]. In HCC, a growing number of genes have been identified as undergoing aberrant promoter hypermethylation, suggesting that promoter hypermethylation is an important molecular mechanism for hepatocarcinogenesis. These include the genes *p16*, *p15* and *RASSF1A* [14,15]. These epigenetic changes have also been implicated as early events in the development of HCC [16–18]. In recent studies, we found promoter hypermethylation of *Hint1* in a subset of both colon cancer and HCC cell lines [9,19].

With the above findings as a background, in the present study, we investigated the *Hint1* promoter methylation profile in HCC and paired adjacent non-tumor DNA samples from patients and also explored the correlation between *Hint1* methylation status and other biomarkers and clinical parameters.

2. Materials and methods

2.1. Patient population and data on clinical parameters

The study samples consisted of 40 frozen dissected tumor and paired adjacent non-tumor tissues, collected in the Department of Surgery, National Taiwan University Hospital. Informed consent was obtained from patients, and the study was approved by the appropriate institutional review committees. Demographic data and clinicopathological characteristics were obtained from hospital charts, and HBV and HCV status was determined by immunoassay

(see Table 1). The criteria for HCC grade are based on the World Health Organization classification [20]. Fourteen normal control liver tissues were obtained from subjects affected with intrahepatic stones, liver cysts, and other non-cancerous diseases identified at the National Taiwan University Hospital. Eight US normal control liver tissues were from subjects affected with heart disease identified at Columbia Presbyterian Hospital in New York City.

2.2. Immunohistochemical detection of *Hint1* protein in paraffin-embedded sections

Detection of the HINT1 protein in 5 μ m paraffin-embedded sections used a commercial polyclonal antibody (ProteinTech Group Inc. Campbell Park Dr., Chicago, IL). The specificity of the anti-Hint1 polyclonal antibody was confirmed by Western blot analysis of a human breast cancer cell line MCF-7 whole cell lysate and a *Hint1* gene knocked out (*Hint1* $-/-$) mouse embryonic fibroblast (MEF) cell line whole cell lysate. The Hint1 antibody is highly specific since there is only one major band (13 kD for HInt1) detected from the MCF-7 whole cell lysate (data not shown). After deparaffinization and rehydration in graded ethanol, the slides were immersed in 10 mM citric acid (pH 6.0) and microwaved for 10 min at 400 W. Staining was carried out according to the manufacture's instruction: the primary antibody (1:400 dilution) was added and sections were incubated overnight at 4 °C. This was followed by adding the secondary antibody and ABC reagent and DAB (both ABC and DAB kits were from Vector Laboratories, Burlingame, CA). Slides were then counterstained with Harris hematoxylin (Sigma, St. Louis, MO). The following categories were used for scoring: intensity of staining, none (0), mild (1), moderate (2), strong (3); and percentage of positive staining, <5% (0), 5–25% (1), 25–50% (2), >50% (3) of cells [21]. Combining intensity and percentage staining resulted in the following score 0–1; negative (–); 2–6 positive (+). Liver sections from wild type (*Hint1* $+/+$) and *Hint1* knocked out (*Hint1* $-/-$) mice [7] were used as positive and negative controls.

2.3. Real time RT-PCR

To test Hint1 expression in normal liver tissues, Western blot and real time RT-PCR was carried out on 3 US normal liver tissues. Primers used in the RT-PCR: hHint1-E1-F1: 5'-TTCTTCCGAGCCTCTCCTCT-3'; hHint1-E1-R1: 5'-GA CGATACCCACCTCAGCAG-3'. GAPDH-F, 5'-AACTT TGGCAT TGTGGAAGG-3'; GAPDH-R, 5'-ACACATTGGG GGTAGGAA CA-3'. A 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) was used for testing.

2.4. DNA extraction

DNA was isolated from frozen tissue samples, as previously described [22]. Briefly, tissue was placed in liquid nitrogen and pulverized with a blender. The tissue powder was lysed with a DNA lysing buffer (10 mM Tris, 10 mM NaCl, 0.1% sodium dodecyl sulfate at pH 7.9, and 200 μ g/ml proteinase K). DNA was isolated by RNase treatment, phenol/chloroform extraction and ethanol precipitation.

Table 1

Demographics, HCV status, HBsAg status and tumor characteristics of HCC cases.

ID	Age	Gender ^a	Cirrhosis in non-tumorous tissue	Grade	Anti-HCV	HBsAg
F003	NA ^b	NA	NA	NA	NA	NA
F004	67	M	+	II	+	+
F005	47	M	—	II	—	+
F006	70	F	—	I	+	—
F007	NA	NA	NA	NA	NA	NA
F008	NA	M	NA	NA	NA	NA
F009	56	M	—	NA	NA	+
F011	NA	NA	NA	NA	NA	NA
F012	39	M	—	III	+	+
F013	78	M	+	II–III	—	+
F014	42	M	—	III	—	+
F015	NA	NA	NA	NA	NA	NA
F017	70	F	—	II	+	—
F018	51	M	—	II	—	+
F019	20	M	—	MI	—	+
F020	NA	NA	NA	NA	NA	NA
F021	45	M	—	II	—	+
F022	58	M	+	I	+	—
F023	43	M	—	II	—	+
F025	51	M	—	II	+	—
F028	35	F	—	III	NA	+
F029	49	M	+	II	—	+
F030	37	M	—	II	—	+
F032	50	M	—	II	—	+
F033	48	M	—	III	+	+
F034	44	M	—	MI	NA	+
F035	49	M	+	III–IV	—	+
F036	62	F	+	III	+	+
F038	62	M	+	II	+	+
F039	69	M	+	III	—	—
F040	76	M	—	III	—	+
F042	40	M	—	II	NA	+
F043	59	F	+	III	—	+
F044	NA	NA	NA	NA	NA	NA
F045	63	M	+	II	—	+
F047	45	M	+	II	—	+
F048	68	M	+	II	NA	+
B115	45	M	+	NA	—	+
B169	53	M	NA	NA	—	—
D145	58	M	NA	NA	+	NA

^a M, male; F, female.^b NA, data not available.

2.5. Analysis of *Hint1* and *p16* hypermethylation status: methylation-specific polymerase chain reaction (MSP)

MSP was carried out, essentially, as described previously [23] and was based on the principle that treating DNA with sodium bisulfite results in the conversion of unmethylated cytosine residues into uracil. Thus, the sequence of the treated DNA will differ if the DNA is originally methylated, and is then distinguishable by sequence-specific PCR primers. Bisulfite modification of tissue DNA was conducted with the CpGnome DNA modification kit (Chemicon International, Temecula, CA). Primers were designed by using Meth-Primer Software; the sense and antisense primers for the methylated *Hint1* promoter were 5'-TTTGGCTAGGTTTGG TTGC-3' and 5'-AACAATCTCATCTACCATCTCGAC-3', respectively, and the primers to detect the unmethylated *Hint1* were 5'-TATTTGTGAGGTTTGGTTGTGT-3' and 5'-AACAATC TCATCTACCATCTCAAC-3', respectively. PCR products were analyzed by agarose gel electrophoresis and ethidium bromide staining. Universal methylated DNA (Chemicon

International) was used as a positive control with distilled water as a negative control.

Data on *p16* methylation and AFB₁- and PAH-DNA adducts on these samples were available from our previous studies [14].

2.6. Statistical analysis

Fisher's exact tests were performed to evaluate the significance of the differences between the frequencies of *Hint1* promoter hypermethylation status of the various tissue categories, comparisons with *Hint1* protein expression status, and comparisons with clinical characteristics.

3. Results

3.1. *Hint1* methylation status

Methylation of the promoter region of *Hint1*, determined by MSP, was frequent in the HCC tumors, with 22 of 40 (55.0%) samples positive. For the paired adjacent non-tumor tissue samples, 15 of 40 samples were posi-

tive samples (37.5%) (Table 2). Representative examples of the gel analysis of MSP are shown in Fig. 1. Interestingly, unmethylated *Hint1* alleles were also detected in all of samples. In the 22 normal liver controls, 14 samples were from Taiwan; 2 of 22 had promoter hypermethylation, none of the US normal controls liver samples had promoter hypermethylation.

3.2. Expression of the *Hint1* protein in liver tissue samples

To determine whether the hypermethylation of CpG islands in the promoter region of *Hint1* in HCC tissues was correlated with loss of expression of the HINT1 protein, immunohistochemical staining using an anti-HINT1 antibody was carried out on 40 HCC tissue sections, 39 adjacent non-tumor sections and 22 normal controls. Representative examples of HINT1 protein expression in HCC samples are shown in Fig. 2 (A and B). Fifteen of the 18 unmethylated HCC samples (83%) demonstrated positive nuclear and cytoplasmic staining and 14 of 22 methylated HCCs (64%) showed loss of expression of *Hint1* (Table 2). Thus, the immunostaining results were strongly correlated ($p=0.003$) with *Hint1* methylation status (Table 4). Representative examples of *Hint1* protein expression in adjacent non-tumor tissues are shown in Fig. 2(C and D). Twenty one of the 24 unmethylated HCC samples (87%) demonstrated positive nuclear and cytoplasmic staining and 8 of 15 methylated HCCs (53%) showed loss of expression of *Hint1* (Table 3). The immunostaining results were strongly correlated ($p=0.01$) with

Table 2
Hint1 gene promoter hypermethylation status and protein expression in Taiwan HCC samples.

	Hypermethylation status		Protein expression	
	Tumor	Adjacent non-tumor	Tumor	Adjacent non-tumor
3	—	—	+	+
4	—	—	+	+
5	—	—	+	+
6	—	+	+	—
7	+	+	—	—
8	—	—	+	+
9	—	—	+	—
11	+	—	+	+
12	+	—	—	—
13	+	+	—	—
14	—	—	+	—
15	+	—	—	—
17	—	+	—	—
18	—	+	—	—
19	—	—	+	+
20	+	—	—	+
21	—	—	+	+
22	+	+	—	+
23	+	+	—	+
25	+	+	—	—
28	+	+	+	+
29	—	—	—	+
30	+	+	+	+
32	+	+	+	—
33	+	—	—	+
34	+	+	—	—
35	+	+	+	+
36	+	+	+	+
38	+	—	+	+
39	—	—	+	+
40	+	—	+	+
42	—	—	+	+
43	+	—	—	+
44	—	—	+	+
45	—	—	+	+
47	+	—	—	+
48	—	—	+	+
B115	—	—	+	+
B169	+	—	—	+
D145	+	+	—	+

Fig. 1. Methylation analysis of *Hint1* in DNA from HCC tissues, the HepG2 HCC cell line was used as a positive control. (1) Bisulfite-treated DNA was used for PCR amplification using primers sets designed for methylated (m) and unmethylated (u) *Hint1*. M, molecular weight marker (100 bp); 1, DNA from the HepG2 HCC cell line; lines 2–6 DNA from 5 HCC cases; line 7, distilled water as negative control.

Hint1 methylation status. Representative examples of *Hint1* protein expression in normal liver control tissues are shown in Fig. 2(E and F). Nineteen of the 20 unmethylated HCC samples (95%) demonstrated positive nuclear and cytoplasmic staining and 2 of 2 methylated HCCs (100%) showed loss of expression of *Hint1* (Table 3). The immunostaining results were strongly correlated ($p=0.01$) with *Hint1* methylation status. Immunohistochemistry staining on liver sections from wild type (*Hint1*+/+) and *Hint1* knocked out (*Hint1*-/-) mice [7], used as positive and negative controls, are shown in Fig. 2(G and H).

Hint1 expression, detected in normal liver tissues by Western blot, Real-Time RT-PCR and immunohistochemical staining, on 3 US normal control tissues is consistent (Data are not shown).

3.3. Relationship between *Hint1* hypermethylation and clinical parameters and other biomarkers

Possible associations between the methylation status of *Hint1* and tumor stage, liver cirrhosis status, HBV infection status, *p16* methylation status and levels of AFB₁- and PAH-DNA adducts were investigated (Table 3). We found that *p16* hypermethylation was statistically significantly associated with *Hint1* methylation status ($p=0.035$), but there was no significant correlation with the other parameters.

4. Discussion

Hypermethylation of CpG islands in their promoter regions is an important mechanism for loss of function of several tumor suppressor genes, DNA repair genes and other genes in various types of human cancer [13]. An increasing number of genes have been reported to undergo CpG island hypermethylation in HCC, which indicates the potential role of epigenetics in hepatocarcinogenesis [24]. The promoters of ras association domain family 1A (*RASS-F1A*) [14], *p16^{INK4a}* [25], *p15^{INK4b}* [26], O⁶-methylguanine-DNA methyltransferase (*MGMT*) [27], glutathione S-transferase pi (*GSTP1*) [16,28], suppressor of cytokine signaling 1 (*SOCS-1*) [29], adenomatous polyposis coli (*APC*) [16] and E-cadherin (*E-Cad*) [30] are the most frequently methylated in HCC. These findings suggest that CpG island hypermethylation is an important molecular mechanism in the development of HCC.

In previous investigations with genetically engineered mice, evidence was obtained that *Hint1* is a novel haploinsufficient tumor suppressor gene [7]. However, its precise mechanism of action and relevance to specific types of human cancer is still not clear. We found a low level of expression of the HINT1 protein in the SW480 cell line when compared with four other human colon cancer cell lines and obtained evidence that this is due to methylation of the promoter region of *Hint1* [9]. In recent studies, we also found a low level of expression of the HINT1 protein in the human HCC cell lines HepG2 and Hep3B when com-

Fig. 2. Immunohistochemical detection of HINT1 expression in liver tissue samples. (A) HCC tissue with unmethylated *Hint1* illustrating expression of the protein in both tumor cell nuclei and cytoplasm, 400 $\times$. (B) HCC tissue with methylated *Hint1* illustrating lack of expression in tumor cells, 400 $\times$. (C) Adjacent non-tumor tissue with unmethylated *Hint1* illustrating expression of the protein in both hepatocyte nuclei and cytoplasm, 400 $\times$. (D) Adjacent non-tumor tissue with methylated *Hint1* illustrating lack of expression in hepatocytes, 400 $\times$. (E) Normal control liver tissue with unmethylated *Hint1* illustrating expression of the protein in both nuclei and cytoplasm of hepatocytes, 400 $\times$. (F) Normal control liver tissue with methylated *Hint1* illustrating lack of expression in hepatocytes, 400 $\times$. (G) Liver tissue from wild type (*Hint1*^{+/+}) mice, used as a positive control, showing *Hint1* expression in hepatocyte nuclei and cytoplasm, 400 $\times$. (H) Liver tissue from *Hint1* knocked out (*Hint1*^{-/-}) mice, used as a negative control, showing lack of expression in hepatocytes, 400 $\times$.

pared with the human HCC cell line Huh7, by western blot analysis, and that this was also due to promoter methylation in the HepG2 and Hep3B cell lines [19]. Other investigators found decreased expression of *Hint1* in a subset of human NSCLC cell lines, which appeared to be due to promoter hypermethylation based on studies utilizing 5-Aza-dC [10]. Thus, decreased expression of HINT1 due to hypermethylation of the promoter region of the *Hint1* gene can occur in at least 3 types of human cancer cell lines.

Based on the above findings, in the present study, we investigated promoter hypermethylation of *Hint1* in DNA samples from primary HCC, paired adjacent non-tumor tissues from patients with HCC, and normal liver tissue DNA. Twenty-two of the 40 (55.0%) HCC samples displayed *Hint1* gene promoter hypermethylation. Methylation was also observed in 37.5% of the paired adjacent non-tumor tissues. This may be due to the fact that these tissue samples were not microdissected and, therefore, they may have been contaminated with a small population of HCC cells. Altern-

tively, since most of the adjacent non-tumorous tissues are cirrhotic, promoter hypermethylation of *Hint1* may be an early event in hepatocarcinogenesis [17], as is the case with other tumor suppressor genes [31]. Interestingly, hypermethylation of *Hint1* was also found in two normal control liver tissues, both from Taiwan and both HBV positive, but not in the 8 normal control liver tissues from the US which were HBV negative. In accordance with our findings, DNA methylation of other tumor suppressor gene has been detected at a low frequency in histologically normal liver tissues [32].

In the present study, the HINT1 protein was detected in 15 of 18 (83%) tumor tissues with *Hint1* promoter not methylated and 8 of 22 (36%) tumor tissues with *Hint1* promoter methylated (*p* value for Fisher's exact test = 0.003). Results were similar for adjacent non-tumor tissues, suggesting that methylation status correlates inversely with HINT1 expression. The discordant data may be due to the lack of tissue microdissection resulting in contamination

Table 3

Gene promoter hypermethylation status and protein expression in control samples.

	Hypermethylation status	Protein expression
T1	–	+
T2	+	–
T3	–	+
T4	–	+
T5	–	+
T6	–	+
T7	–	+
T8	–	+
T9	+	–
T10	–	+
T11	–	+
T12	–	+
T13	–	–
T14	–	+
US1	–	+
US2	–	+
US3	–	+
US4	–	+
US5	–	+
US6	–	+
US7	–	+
US8	–	+

Table 4

The association of clinical characteristics with *Hint1* methylation status.

Variable	Tumor tissues		P
	Non-methylated	Methylated	
<i>Adjacent non-tumor tissues</i>			
Non-methylated	15	9	0.01
Methylated	3	12	
Missing	0	1	
<i>Hint 1 protein expression</i>			
No	3	14	0.003
Yes	15	8	
<i>Grade</i>			
I or II	11	8	0.49
III or IV	2	8	
Missing	5	6	
<i>Liver cirrhosis</i>			
No	9	9	0.71
Yes	6	7	
Missing	3	6	
<i>HBsAg</i>			
Negative	3	2	0.44
Positive	12	15	
Missing	3	5	
<i>Aflatoxin B1-adducts</i>			
Low	11	7	0.07
Medium	3	11	
High	4	4	
<i>PAH-adducts</i>			
Low	9	13	0.49
Medium	4	7	
High	4	2	
Missing	1	0	
<i>p16 methylation</i>			
No	10	5	0.035
Yes	8	17	

of the tumor tissue with adjacent non-tumor tissue. Immunohistochemical staining of small pieces of tissue also limits the detection of protein expression and post-translation

protein degradation may also help explain the discordant data. Discrepancies between Methylation Specific PCR (MSP) and immunohistochemistry detection was reported previously [26,33].

The frequencies of hypermethylation of *Hint1* in tumor and paired adjacent non-tumor tissues were 55.0% and 37.5%, respectively. The difference in promoter methylation frequencies between tumor and surrounding tissues is not statistically significant ($p = 0.121$). Most non-tumor tissues adjacent to HCC have a background of cirrhosis, chronic hepatitis infection, regenerative lesions (focal nodular hyperplasia) and other chronic liver injury. Previous studies reported that gene promoter hypermethylation is correlated with HBV-associated HCC [34] and that liver tissue adjacent to a tumor clearly harbors alterations in the DNA methylation patterns that are related to aberrant hypermethylation in the tumor tissues [35]. This epigenetic alteration in nonneoplastic tissues adjacent to HCC could be explained by field cancerization and implied *Hint1* promoter hypermethylation could be one of the early events in the development of HCC.

Promoter hypermethylation of some genes is significantly linked to pathological or clinical parameters. For example, *p16* hypermethylation is associated with HBV infection and expression of the HBV $\times$ protein [36,37]. In our previous studies, statistically significant associations were found between *RASSF1A*, *p16*, and *MGMT* methylation status and the levels of AFB₁-DNA adducts in Taiwan HCC samples [14,27]. *SOCs-1* silencing is significantly involved in the development of HCC from liver cirrhosis [29], and hypermethylation of *E-Cad* or *GSTP1* correlates with poor survival in HCC patients [24]. In the present study, the correlations between *Hint1* methylation and HBV and HCV infections status and AFB₁- and PAH-DNA adduct levels were also investigated, but no statistically significant correlations were found. Perhaps, HBV and HCV infections and chemical carcinogens like AFB₁ and PAHs do not affect *Hint1* promoter methylation status, although the relatively small sample size may limit this analysis.

Previous studies determined the frequency and chronology of methylation events of specific genes during the multistep process of hepatocarcinogenesis from cirrhosis to HCC. CpG island hypermethylation occurs in the pre-malignant stages and tends to accumulate during multistep hepatocarcinogenesis. The data suggests that CpG island hypermethylation of *COX-2* or *p16* might be potential molecular markers for the identification of patients with chronic liver disease at high risk for progression to HCC [24]. Another study suggested that the most striking methylation pattern in HCC is the concurrent methylation of multiple tumor suppressor genes (TSG). Although methylation of one or two genes can be observed in non-tumor and cirrhotic liver tissue, the majority of HCC cases harbored three or more methylated TSGs [16]. In present study, *Hint1* methylation was significantly associated with *p16* hypermethylation ($p = 0.035$). This finding is consistent with previous studies and provides further evidence that several TSGs genes accumulate methylation during progression from pre-malignant stages to HCC.

In our previous studies on mechanisms of *Hint1*, the results suggested that *Hint1* inhibits AP-1 activity by binding

to a POSH-JNK2 complex, thus inhibiting the phosphorylation of c-Jun, this effect could contribute to the tumor suppressor activity of Hint1 [9]. Decreased expression of the *Hint1* gene through epigenetic silencing may play a role in enhancing the growth of a subset of human hepatoma cell lines by increasing the expression of genes controlled by the transcription factors β -catenin, USF2 and NF κ B [19].

In conclusion, to the best of our knowledge, this is the first study on detection of *Hint1* promoter hypermethylation in tumor tissues. Our investigation demonstrated that epigenetic inactivation of *Hint1* is a frequent event in the development of HCC and promoter hypermethylation of *Hint1* can be an early event in hepatocarcinogenesis. The biologic basis and mechanisms of *Hint1* inactivation by hypermethylation and the relationship between epigenetic changes in *Hint1* and other risk factors for HCC is not clear at the present time. Additional studies with larger sample sizes are required to elucidate these aspects. We believe that these studies of environment-epigenetic interactions are necessary for a deeper understanding of HCC and the mechanism of action of carcinogenic exposures and could be used to identify novel opportunities for the prevention and therapy of HCC.

Conflict of interest

None of all authors for this paper has conflict of interest statement.

Acknowledgements

This work was supported by grants from the National Institutes of Health (ES05116 and P30ES009089) to Dr. Regina M. Santella and funds from the T.J. Martell Foundation and the National Foundation for Cancer Research to Dr. I. Bernard Weinstein.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.canlet.2008.10.042](https://doi.org/10.1016/j.canlet.2008.10.042).

References

- [1] H.B. El-Serag, A.C. Mason, Rising incidence of hepatocellular carcinoma in the United States, *N. Engl. J. Med.* 340 (1999) 745–750.
- [2] F.X. Bosch, J. Ribes, R. Cleries, M. Diaz, Epidemiology of hepatocellular carcinoma, *Clin. Liver Dis.* 9 (2005) 191–211.
- [3] F.X. Bosch, J. Ribes, J. Borrás, Epidemiology of primary liver cancer, *Semin. Liver Dis.* 19 (1999) 271–285.
- [4] N. Kondoh, T. Wakatsuki, A. Hada, M. Shuda, K. Tanaka, M. Arai, et al., Genetic and epigenetic events in human hepatocarcinogenesis, *Int. J. Oncol.* 18 (2001) 1271–1278.
- [5] C. Brenner, Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases, *Biochemistry* 41 (2002) 9003–9014.
- [6] T. Su, M. Suzui, L. Wang, C.S. Lin, W.Q. Xing, I.B. Weinstein, Deletion of histidine triad nucleotide-binding protein 1/PTK-interacting protein in mice enhances cell growth and carcinogenesis, *Proc. Natl. Acad. Sci. USA* 100 (2003) 7824–7829.
- [7] H. Li, Y. Zhang, T. Su, R.M. Santella, I.B. Weinstein, Hint1 is a haploinsufficient tumor suppressor in mice, *Oncogene* 25 (2006) 713–721.
- [8] J. Weiske, O. Huber, The histidine triad protein Hint1 triggers apoptosis independent of its enzymatic activity, *J. Biol. Chem.* 281 (2006) 27356–27366.
- [9] L. Wang, Y. Zhang, H. Li, Z. Xu, R.M. Santella, I.B. Weinstein, Hint1 inhibits growth and activator protein-1 activity in human colon cancer cells, *Cancer Res.* 67 (2007) 4700–4708.
- [10] B.Z. Yuan, A.M. Jefferson, N.C. Popescu, S.H. Reynolds, Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2'-deoxycytidine, *Neoplasia* 6 (2004) 412–419.
- [11] S.B. Baylin, J.G. Herman, DNA hypermethylation in tumorigenesis: epigenetics joins genetics, *Trends Genet.* 16 (2000) 168–174.
- [12] K.H. Yu, Y.M. Lo, G.M. Tse, K.C. Chan, A.B. Chan, K.C. Chow, et al., Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas, *Clin. Cancer Res.* 10 (2004) 1726–1732.
- [13] S.B. Baylin, J.G. Herman, J.R. Graff, P.M. Vertino, J.P. Issa, Alterations in DNA methylation: a fundamental aspect of neoplasia, *Adv. Cancer Res.* 72 (1998) 141–196.
- [14] Y.J. Zhang, H. Ahsan, Y. Chen, R.M. Lunn, L.Y. Wang, S.Y. Chen, et al., High frequency of promoter hypermethylation of the RASSF1A and p16 genes and its relationship to aflatoxin B1-DNA adducts level in human hepatocellular carcinoma, *Mol. Carcinog.* 35 (2002) 85–92.
- [15] M. Esteller, P.G. Corn, S.B. Baylin, J.G. Herman, A gene hypermethylation profile of human cancer, *Cancer Res.* 61 (2001) 3225–3229.
- [16] B. Yang, M. Guo, J.G. Herman, D.P. Clark, Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma, *Am. J. Pathol.* 163 (2003) 1101–1107.
- [17] Y.J. Zhang, H.C. Wu, J. Shen, H. Ahsan, W.Y. Tsai, H.I. Yang, et al., Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA, *Clin. Cancer Res.* 13 (2007) 2378–2384.
- [18] H. Murata, S. Tsuji, M. Tsujii, Y. Sakaguchi, H.Y. Fu, S. Kawano, et al., Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells, *Lab. Invest.* 84 (2004) 1050–1059.
- [19] L. Wang, H. Li, Y.J. Zhang, A. Harada, R. Santella, I. Weinstein, Hint1 inhibits B-catenin/TCF4, USF2 and NF κ B activity in human hepatoma cells, *Int. J. Cancer*, in press.
- [20] M. Kojima, Pathology of Hepatocellular Carcinoma, Blackwell Publishing Ltd., 2006.
- [21] Y.J. Zhang, P. Rossner, Y. Chen, M. Agrawal, Q. Wang, L. Wang, et al., Aflatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients, *Int. J. Cancer* 119 (2006) 985–991.
- [22] W. Jiang, Y.J. Zhang, S.M. Kahn, M.C. Hollstein, R.M. Santella, S.H. Lu, et al., Altered expression of the cyclin D, and retinoblastoma genes in human esophageal cancer, *Proc. Natl. Acad. Sci. USA* 90 (1993) 9026–9030.
- [23] J.G. Herman, J.R. Graff, S. Myohanen, B.D. Nelkin, S.B. Baylin, Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands, *Proc. Natl. Acad. Sci. USA* 93 (1996) 9821–9826.
- [24] S. Lee, H.J. Lee, J.H. Kim, H.S. Lee, J.J. Jang, G.H. Kang, Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis, *Am. J. Pathol.* 163 (2003) 1371–1378.
- [25] C.T. Liew, H.M. Li, K.W. Lo, C.K. Leow, J.Y. Chan, L.Y. Hin, et al., High frequency of p16INK4A gene alterations in hepatocellular carcinoma, *Oncogene* 18 (1999) 789–795.
- [26] I.H. Wong, Y.M. Lo, W. Yeo, W.Y. Lau, P.J. Johnson, Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients, *Clin. Cancer Res.* 6 (2000) 3516–3521.
- [27] Y.J. Zhang, Y. Chen, H. Ahsan, R.M. Lunn, P.H. Lee, C.J. Chen, et al., Inactivation of the DNA repair gene O⁶-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutations in hepatocellular carcinoma, *Int. J. Cancer* 103 (2003) 440–444.
- [28] M. Esteller, P.G. Corn, J.M. Urena, E. Gabrielson, S.B. Baylin, J.G. Herman, Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia, *Cancer Res.* 58 (1998) 4515–4518.
- [29] O. Okochi, K. Hibi, M. Sakai, S. Inoue, S. Takeda, T. Kaneko, et al., Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis, *Clin. Cancer Res.* 9 (2003) 5295–5298.
- [30] T. Matsumura, R. Makino, K. Mitamura, Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas, *Clin. Cancer Res.* 7 (2001) 594–599.

- [31] S.A. Belinsky, K.J. Nikula, W.A. Palmisano, R. Michels, G. Saccomanno, E. Gabrielson, et al., Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis, *Proc. Natl. Acad. Sci. USA* 95 (1998) 11891–11896.
- [32] Y. Kondo, Y. Kanai, M. Sakamoto, M. Mizokami, R. Ueda, S. Hirohashi, Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis – a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma, *Hepatology* 32 (2000) 970–979.
- [33] M. Esteller, S.R. Hamilton, P.C. Burger, S.B. Baylin, J.G. Herman, Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia, *Cancer Res.* 59 (1999) 793–797.
- [34] S. Zhong, M.W. Tang, W. Yeo, C. Liu, Y.M. Lo, P.L. Johnson, Silencing of GSTp1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinoma, *Clin. Cancer Res.* 8 (2002) 1087–1092.
- [35] U. Lehmann, I. Berg-Ribbe, L.U. Wingen, K. Brakensiek, T. Becker, J. Klempnauer, B. Schlegelberger, P. Kreipe Hand Flemming, Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling, *Clin. Cancer Res.* 11 (2005) 3654–3660.
- [36] X. Li, A.M. Hui, L. Sun, K. Hasegawa, G. Torzilli, M. Minagawa, et al., p16INK4A hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma, *Clin. Cancer Res.* 10 (2004) 7484–7489.
- [37] R. Zhu, B.Z. Li, H. Li, Y.Q. Ling, X.Q. Hu, W.R. Zhai, et al., Association of p16INK4A hypermethylation with hepatitis B virus X protein expression in the early stage of HBV-associated hepatocarcinogenesis, *Pathol. Int.* 57 (2007) 328–336.